Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) has received a consensus rating of “Moderate Buy” from the eight brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year price objective among […]
Related Keywords
China , , Fund Management Co , Nasdaq , Kura Oncology Inc , Kura Oncology Company Profile , E Fund Management Co , China Universal Asset Management Co , Kura Oncology , Get Free Report , Fire Capital , Fund Management , China Universal Asset Management , Universal Asset Management , Oncology Stock Down , Get Free , Kura Oncology Daily , Nasdaq Kura , Kura , Medical , Ratings , Consensus ,
comparemela.com © 2020. All Rights Reserved.